Y Intercept Hong Kong Ltd Raises Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Y Intercept Hong Kong Ltd grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 39.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,695 shares of the biopharmaceutical company's stock after purchasing an additional 7,544 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Ultragenyx Pharmaceutical were worth $1,123,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in RARE. Van ECK Associates Corp lifted its stake in Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 273 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock valued at $928,000 after acquiring an additional 294 shares in the last quarter. Motley Fool Asset Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 0.3% during the third quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company's stock valued at $8,005,000 after acquiring an additional 360 shares in the last quarter. KBC Group NV boosted its position in Ultragenyx Pharmaceutical by 24.5% in the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company's stock valued at $143,000 after buying an additional 506 shares during the last quarter. Finally, M&T Bank Corp boosted its position in Ultragenyx Pharmaceutical by 8.1% in the third quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company's stock valued at $388,000 after buying an additional 525 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE traded up $0.95 during midday trading on Friday, hitting $42.92. The company had a trading volume of 910,491 shares, compared to its average volume of 866,523. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37. The firm has a market capitalization of $3.97 billion, a P/E ratio of -6.77 and a beta of 0.60. The company's 50-day simple moving average is $42.91 and its 200-day simple moving average is $49.12.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Wedbush restated a "neutral" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. HC Wainwright reissued a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. JPMorgan Chase & Co. reduced their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a research note on Thursday, November 21st. Canaccord Genuity Group raised their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $93.50.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the business's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the sale, the chief executive officer now directly owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. The trade was a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.